Effects of Mobility Dose on Discharge Disposition in Critically Ill Stroke Patients (NCT03347656) | Clinical Trial Compass
CompletedNot Applicable
Effects of Mobility Dose on Discharge Disposition in Critically Ill Stroke Patients
United States, Germany164 participantsStarted 2017-10-12
Plain-language summary
The primary aim of the study is to assess the mobility dose in neurocritical care patients with ischemic stroke or intracranial hemorrhage and its effects on discharge disposition and patient outcomes. The investigators hypothesize that patients' mobilization dose in the intensive care unit (ICU) predicts discharge disposition, 90 day Barthel Index and other outcomes like muscle wasting (expressed as decrease in rectus femoris cross sectional area (RF-CSA) in the paretic and non-paretic limb measured by bedside ultrasound), and ICU length of stay (LOS).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18 years and older
* Admitted to the neurological intensive care service within the past 48 hours
* an expected ICU length of stay of at least 48h
* New onset ischemic stroke or non-traumatic intracerebral hemorrhage
* Baseline functional independence: Barthel-Index of 70 or above 2 weeks before admission (obtained retrospectively from patient or proxy)
Exclusion Criteria:
* Transfers from other institutions (hospitals, long-term rehabilitation facilities, skilled nursing facilities) with a stay \>48h at the outside institution
* absence of lower extremities
* not committed to full support
* exclusive or clinically predominant posterior circulation ischemic stroke
* subarachnoid hemorrhage, subdural and epidural hemorrhage
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Adverse Hospital Discharge Disposition
Timeframe: patient will be followed until hospital discharge; assessed at hospital discharge; expected between study day 3 and 30
2
90 day Barthel Index (hierarchical testing)
Timeframe: 90 days post discharge from hospital (collected through follow up phone call)